Executive Director, Investor Relations

What's happening at Entrada Therapeutics? Entrada is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary and versatile approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others.

Our lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy (DMD) who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered with Vertex Pharmaceuticals to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1 (DM1).

2026 represents a catalyst-rich period for Entrada. We expect multiple clinical data readouts as we advance several DMD programs across the U.K., EU, and U.S. By year-end 2026, we anticipate four clinical-stage programs in our DMD franchise (ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51). These programs are complemented by the ongoing clinical progress of our DM1 collaboration with Vertex (VX-670).

We are a tight-knit team of experts and leaders in both therapeutic development and rare diseases and are excited to grow and attract colleagues who are ready to join a high-energy, dedicated team that likes to get things done and dramatically improve the lives of patients and their families.

You are intellectually curious and can bring new ideas and perspectives to lead the development, implementation, and management of our investor relations function. You follow up and follow through, efficiently connecting problems with solutions. You work successfully in a fast-paced team environment and have strong interpersonal skills, effectively building working relationships with leaders across the Company and with outside parties.

The Executive Director, Investor Relations will be responsible for developing and executing a comprehensive investor relations strategy that enhances Entrada’s visibility, credibility, and positioning within the financial community and broader stakeholder landscape. Reporting to the Chief Financial Officer, the ideal candidate will combine deep investor relations and financial expertise with strong scientific and clinical fluency to build investor confidence, drive awareness, and support long-term shareholder value creation for a NASDAQ-listed biotechnology company with an expanding portfolio of clinical-stage programs.

• Drive the strategic direction, planning, and execution of the investor relations function, including financial communications, while building and continuously strengthening a best-in‑class investor relations program.
• Serve as a trusted advisor to senior leadership by providing insight and guidance on investor messaging, communications effectiveness, market dynamics, and investor sentiment.
• Act as the primary point of contact to the investment community, responding to external inquiries in an accurate, appropriate, and timely manner; establish and maintain strong relationships with biotechnology-focused buy‑side and sell‑side analysts and institutional investors.
• Develop and maintain proactive engagement with investors and analysts to clearly communicate the Company’s long‑term vision, clinical and platform strategy, differentiation, opportunity, risk factors, and key milestones.
• Lead the development and coordination of financial and investor communications—including earnings releases, investor webcasts, investor presentations, Company corporate presentations and investor relations section of the Company website
• Coordinate cross‑functionally with Finance and Legal to support the timely and compliant execution of external financial disclosures and investor communications including periodic reports (Form 10‑K and Form 10‑Q), annual proxy statements and other reports.
• Lead the Company’s participation in investment community events, including investor conferences, non‑deal roadshows, analyst days, and targeted investor meetings.
• Devel…